TCGA-CR-7388-01A-11R-2016-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 0.187899543
- sex
- female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_UP+0.300
- KRAS_SIGNALING_DN+0.290
- IL6_JAK_STAT3_SIGNALING+0.260
- INFLAMMATORY_RESPONSE+0.260
- PANCREAS_BETA_CELLS+0.190
- UV_RESPONSE_DN+0.130
- ALLOGRAFT_REJECTION+0.120
- APICAL_SURFACE+0.120
- COAGULATION+0.120
- HEDGEHOG_SIGNALING+0.100
Top 10 suppressed
- MYC_TARGETS_V2-0.610
- MYC_TARGETS_V1-0.580
- INTERFERON_ALPHA_RESPONSE-0.550
- E2F_TARGETS-0.520
- OXIDATIVE_PHOSPHORYLATION-0.500
- DNA_REPAIR-0.490
- MTORC1_SIGNALING-0.430
- UNFOLDED_PROTEIN_RESPONSE-0.390
- GLYCOLYSIS-0.370
- G2M_CHECKPOINT-0.360
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-2478 | Med | Medulloblastoma | 0.880 |
| 2 | AUR-AD9J-TTP1-B-4-0-R-A584-39 | — | D | 0.877 |
| 3 | SRR12202446 | — | — | 0.876 |
| 4 | SJEPD031111_D1.RNA-Seq | EPN | EPN Tumor | 0.864 |
| 5 | SRR1360104 | GTEX | — | 0.861 |
| 6 | C3L-03268 | — | cohortA1 | 0.860 |
| 7 | SRR8942991 | — | — | 0.857 |
| 8 | SRR10900012 | — | — | 0.855 |
| 9 | SRR1416410 | GTEX | — | 0.855 |
| 10 | C3N-03911 | — | cohortA1 | 0.854 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_UP | 0.300 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.290 | Remibrutinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.260 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.260 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.190 | Cobimetinib | — uncovered |
| UV_RESPONSE_DN | 0.130 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.120 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.120 | Temsirolimus | — uncovered |
| COAGULATION | 0.120 | Binimetinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.100 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.080 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.080 | Inavolisib | — uncovered |
| COMPLEMENT | 0.060 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.040 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.020 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.010 | Idelalisib | — uncovered |